Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat

1993 ◽  
Vol 138 (2) ◽  
pp. 259-266 ◽  
Author(s):  
L. M. Burrell ◽  
P. A. Phillips ◽  
J. Stephenson ◽  
J. Risvanis ◽  
A.-M. Hutchins ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Rat Liver ◽  
Renal Medulla ◽  
Kinetic Studies ◽  
Dependent Manner ◽  
Kidney Medulla ◽  
Liver And Kidney

ABSTRACT A non-peptide, orally effective, vasopressin (AVP) V1 receptor antagonist 1-{1-[4-(3-acetylaminopropoxy) benzoyl]-4-piperidyl}-3,4-dihydro-2(1H)-quinolinone (OPC-21268) has recently been described. This paper reports the in-vitro and in-vivo characterization of OPC-21268 binding to vasopressin receptors in rat liver and kidney. OPC-21268 caused a concentration-dependent displacement of the selective V1 receptor antagonist radioligand, 125I-labelled [d(CH2)5,sarcosine7]AVP to V1 receptors in both rat liver and kidney medulla membranes. The concentration of OPC-21268 that displaced 50% of specific AVP binding (IC50) was 40±3 nmol/l for liver V1 and 15±2 nmol/l for kidney V1 receptors (mean ± s.e.m.; n = 3). OPC-21268 had little effect on the selective V2 antagonist radioligand [3H]desGly-NH29[d(CH2)5,d-Ile2,Ile4] AVP binding to V2 receptors in renal medulla membranes (IC50 >0·1 mmol/l). After oral administration to rats, OPC-21268 was an effective V1 antagonist in a time- and dose-dependent manner. Binding kinetic studies showed that OPC-21268 acted as a competitive antagonist at the liver V1 receptor in vitro and in vivo, in addition to its in-vitro competitive effects at the renal V1 receptor. OPC-21268 shows promise as an orally active V1 antagonist. Journal of Endocrinology (1993) 138, 259–266

Characterization of 3-carboxy-5-phosphono-1,2,3,4-tetrahydroisoquinoline (SC-48981), a potent competitive (NMDA) receptor antagonist, in vitro and in vivo

1992 ◽  
Vol 135 (2) ◽  
pp. 149-152 ◽  
Author(s):  
Michael L. Vazquez ◽  
Danny J. Garland ◽  
Eric T. Sun ◽  
Julie A. Cler ◽  
Steve J. Mick ◽  
...  
Keyword(s):  
Nmda Receptor ◽  
Receptor Antagonist ◽  
Nmda Receptor Antagonist

scholarly journals PRIC295, a Nuclear Receptor Coactivator, Identified from PPAR-Interacting Cofactor Complex

PPAR Research ◽  
2010 ◽  
Vol 2010 ◽  
pp. 1-16 ◽  
Author(s):  
Sean R. Pyper ◽  
Navin Viswakarma ◽  
Yuzhi Jia ◽  
Yi-Jun Zhu ◽  
Joseph D. Fondell ◽  
...  
Keyword(s):  
Nuclear Receptor ◽  
Target Genes ◽  
Peroxisome Proliferator ◽  
Dependent Manner ◽  
Peroxisome Proliferator Activated Receptor ◽  
Nuclear Receptor Coactivator ◽  
Evolutionarily Conserved

The peroxisome proliferator-activated receptor- (PPAR) plays a key role in lipid metabolism and energy combustion. Chronic activation of PPAR in rodents leads to the development of hepatocellular carcinomas. The ability of PPAR to induce expression of its target genes depends on Mediator, an evolutionarily conserved complex of cofactors and, in particular, the subunit 1 (Med1) of this complex. Here, we report the identification and characterization of PPAR-interacting cofactor (PRIC)-295 (PRIC295), a novel coactivator protein, and show that it interacts with the Med1 and Med24 subunits of the Mediator complex. PRIC295 contains 10 LXXLL signature motifs that facilitate nuclear receptor binding and interacts with PPAR and five other members of the nuclear receptor superfamily in a ligand-dependent manner. PRIC295 enhances the transactivation function of PPAR, PPAR, and ER. These data demonstrate that PRIC295 interacts with nuclear receptors such as PPAR and functions as a transcription coactivator underin vitroconditions and may play an important role in mediating the effectsin vivoas a member of the PRIC complex with Med1 and Med24.

scholarly journals Identification of a Bidirectional Splicing Enhancer: Differential Involvement of SR Proteins in 5′ or 3′ Splice Site Activation

1999 ◽  
Vol 19 (11) ◽  
pp. 7347-7356 ◽  
Author(s):  
Cyril F. Bourgeois ◽  
Michel Popielarz ◽  
Georges Hildwein ◽  
James Stevenin
Keyword(s):  
Splice Site ◽  
Sr Proteins ◽  
Dependent Manner ◽  
Wild Type ◽  
Adenovirus E1a ◽  
Differential Involvement ◽  
Splicing Enhancer

ABSTRACT The adenovirus E1A pre-mRNA undergoes alternative splicing whose modulation occurs during infection, through the use of three different 5′ splice sites and of one major or one minor 3′ splice site. Although this pre-mRNA has been extensively used as a model to compare the transactivation properties of SR proteins, no cis-acting element has been identified in the transcript sequence. Here we describe the identification and the characterization of a purine-rich splicing enhancer, located just upstream of the 12S 5′ splice site, which is formed from two contiguous 9-nucleotide (nt) purine motifs (Pu1 and Pu2). We demonstrate that this sequence is a bidirectional splicing enhancer (BSE) in vivo and in vitro, because it activates both the downstream 12S 5′ splice site through the Pu1 motif and the upstream 216-nt intervening sequence (IVS) 3′ splice site through both motifs. UV cross-linking and immunoprecipitation experiments indicate that the BSE interacts with several SR proteins specifically, among them 9G8 and ASF/SF2, which bind preferentially to the Pu1 and Pu2 motifs, respectively. Interestingly, we show by in vitro complementation assays that SR proteins have distinct transactivatory properties. In particular, 9G8, but not ASF/SF2 or SC35, is able to strongly activate the recognition of the 12S 5′ splice site in a BSE-dependent manner in wild-type E1A or in a heterologous context, whereas ASF/SF2 or SC35, but not 9G8, activates the upstream 216-nt IVS splicing. Thus, our results identify a novel exonic BSE and the SR proteins which are involved in its differential activity.

Studies on the Biosynthesis of Flavin Nucleotides from 2-14C-Riboflavin by Rat Liver and Kidney

1973 ◽  
Vol 51 (6) ◽  
pp. 772-782 ◽  
Author(s):  
A. G. Fazekas ◽  
T. Sandor
Keyword(s):  
Rat Liver ◽  
Flavin Adenine Dinucleotide ◽  
Total Radioactivity ◽  
Flavin Mononucleotide ◽  
Time Intervals ◽  
Adult Rats ◽  
Liver And Kidney ◽  
Rat Liver Cytosol

2-14C-Riboflavin was injected subcutaneously into young adult rats to study the biosynthesis of flavin mononucleotide (FMN) and flavin–adenine dinucleotide (FAD) in the liver and kidneys. Animals were sacrificed at different time intervals following the administration of labelled riboflavin (RF), and radioactive flavins were determined in their tissues by a newly devised method. Both tissues accumulated radioactive riboflavin rapidly and peak levels were obtained at 90 min after the injection, when over 80% of the total radioactivity of the liver was present in FAD. At this time the liver contained 17% of the injected dose of 2-14C-RF. The kidneys contained relatively high quantities of free RF due to the concentration and urinary excretion of the vitamin.Analysis of subcellular fractions of the liver of animals injected with 2-14C-RF revealed that most of the radioactivity was present in mitochondria and nuclei. The flavin nucleotides of rat liver cytosol became progressively associated with macromolecules in vivo. However, there was no significant binding of free RF by macromolecules in blood plasma or liver cytosol.Kinetic studies and incubations with liver slices indicated that RF freely diffuses into the liver cells, is rapidly converted into FAD, and becomes attached to apoenzymes. The tissue uptake of RF and FMN formation is considerably influenced by the concentration of RF present in the system, both in vivo and in vitro.

Pharmacological Characterization of the Competitive GLUK5 Receptor Antagonist Decahydroisoquinoline LY466195 in Vitro and in Vivo

2006 ◽  
Vol 318 (2) ◽  
pp. 772-781 ◽  
Author(s):  
Brianne Weiss ◽  
Andrew Alt ◽  
Ann Marie Ogden ◽  
Mary Gates ◽  
Donna K. Dieckman ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Pharmacological Characterization

scholarly journals Effect of a single dose of dimethylnitrosamine on biosynthesis of nucleic acid and protein in rat liver and kidney

1971 ◽  
Vol 125 (4) ◽  
pp. 943-952 ◽  
Author(s):  
B. W. Stewart ◽  
P. N. Magee
Keyword(s):  
Single Dose ◽  
Rat Liver ◽  
Sucrose Density Gradient ◽  
Polymerase Activity ◽  
Hepatic Necrosis ◽  
Deficient Diet ◽  
Morphological Studies ◽  
Liver And Kidney

1. Administration of a single dose of dimethylnitrosamine to rats temporarily fed on a protein-deficient diet causes a high incidence of kidney tumours. The effect of such a dose of dimethylnitrosamine (40mg/kg body wt.) on metabolism of nucleic acids and protein in rat liver and kidneys was examined during the week immediately after administration. 2. Incorporation of [14C]leucine and [14C]orotate into hepatic macromolecules was inhibited within 5h of injection of dimethylnitrosamine, and did not recover for at least 5 days. Interpretation of these results is complicated by the concomitant extensive hepatic necrosis. 3. Renal RNA synthesis was assayed by incorporation of [14C]orotate in vivo and measurement of DNA-dependent RNA polymerase activity in vitro. Both systems indicate biphasic inhibition; minimal activity was recorded 9h and 3 days after treatment. Changes in incorporation of [14C]leucine into renal protein were similar but less marked. 4. Sucrose-density-gradient analysis of renal cytoplasmic RNA indicated increased synthesis of rRNA 24h after injection of the nitrosamine. The rate of loss of radioactivity from kidney ribosomes pre-labelled with [14C]orotate was not modified by dimethylnitrosamine. 5. Dimethylnitrosamine increased incorporation of [3H]-thymidine into renal DNA. The three distinct periods of stimulated synthesis observed are discussed, with particular reference to recently published morphological studies of the sequential development of kidney tumours induced by dimethylnitrosamine in protein-depleted rats.

scholarly journals In Vitro and In Vivo Characterization of the Non-peptide NK3 Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia

2007 ◽  
Vol 33 (7) ◽  
pp. 1642-1652 ◽  
Author(s):  
Lee A Dawson ◽  
Katherine J Cato ◽  
Claire Scott ◽  
Jeannette M Watson ◽  
Martyn D Wood ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Nk3 Receptor ◽  
In Vivo Characterization ◽  
Therapeutic Utility
Sign in / Sign up

Export Citation Format

Share Document